|
|
Article: Study: Two-dose Zenapax reduced incidence of acute organ rejection.
- Article from:
- Blood Weekly
- Article date:
- June 20, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 JUN 20 - (NewsRx.com & NewsRx.net) -- Two doses of the immunosuppressive agent Zenapax (daclizumab) decreased rejection in kidney transplant patients at high risk for delayed organ function, and had cost benefits when compared with OKT3 (muromonab-CD3), another induction treatment used to prevent acute organ rejection, according to a new investigational study comparing the two treatments that was reported at the American Transplant Congress, a joint meeting held annually by the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS).
Transplantation of kidneys that are not considered fully functional, based on ...